At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 304 enrolled
Drug / intervention
CSF-1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)
In Brief
A Phase 3 clinical trial evaluating CSF-1 and Vehicle for Presbyopia. Completed, enrolled 304 participants across 18 sites.
Detailed Summary
This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionJan 2022
Study CompletionJan 2022
TodayJul 2026
First PostedOct 23, 2020
Enrollment StartOct 26, 2020
Primary CompletionJan 21, 2022
Study CompletionJan 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.7 years ago
Interventions
CSF-1drug
One drop bilaterally twice daily for approximately 2 weeks.
Vehicledrug
One drop bilaterally twice daily for approximately 2 weeks.